The majority of patients with psoriatic arthritis treated with disease-modifying antirheumatic drugs will switch medications, discontinue treatment, or add an additional medicine, usually within a few months of initiating treatment.
Psoriatic arthritis may be difficult to distinguish from other types of arthritis. According to results of a new study, assessing a patient’s sense of balance and hearing ability may be an aid in the diagnosis.
Until apremilast was approved earlier this year, patients with psoriatic arthritis had to rely primarily on injectable therapies, which contributed to less than optimal treatment adherence in many patients.
Patients treated with certolizumab pegol for 24 weeks showed rapid improvement in the signs and symptoms of psoriatic arthritis.
The National Psoriasis Foundation (NPF) recently announced a number of new programs and a five-year strategic mission for the organization with initiatives that are designed to increase research and uncover new treatments for all forms of psoriasis and psoriatic disease.
When it was approved by the FDA in March 2014, apremilast became the first oral medication approved for the treatment of psoriatic arthritis (PsA). Data from clinical trials showed it to be an effective option for patients, with a safer side effect profile than currently used PsA treatments.